Citations

Clear

48 citation(s) found for "Stone, John".

2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Langford, Carol A. , Maz, Mehrdad , Abril, Andy , Gorelik, Mark , Archer, Amy M., Conn, Doyt L. , Full, Kathy A., Grayson, Peter C. , Ibarra, Maria, Imundo, Lisa F., Kim, Susan , Rhee, Rennie L. , Stone, John H. , Sule, Sangeeta , Vitobaldi, Omar I., Warner, Ann, Byram, Kevin , Husainat, Nedaa , Kalot, Mohamad A. , Lin, Yih Chang, Springer, Jason , Turgunbaev, Marat, Villa‐Forte, Alexandra, Turner, Amy S. , Maz, Mehrdad , Conn, Doyt L , Grayson, Peter C , Merkel, Peter A , Rhee, Rennie L , Stone, John H , Sule, Sangeeta , Husainat, Nedaa M , Kalot, Mohamad A , Springer, Jason M , Turner, Amy S , Mustafa, Reem A , Chung, Sharon A. , Guyatt, Gordon , Merkel, Peter A. , Seo, Philip , Sundel, Robert P. , Warner, Ann, Dua, Anisha B. , James, Karen E.

Mayo Clinic

Arthritis Care & Research | July 8, 2021 | Volume: 73 | Issue: 8 | Pages: 1088-1105

10.1002/acr.24634 | PMID 34235880 Get It

Objective To provide evidence‐based recommendations and expert guidance for the management of antineutrophil cytoplasmic antibody–associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). Methods Clinical questions regarding the treatment and management of AAV were developed in the population, intervention, comparator, and outcome (PICO) format (47 for GPA/MPA, 34 for EGPA). Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to assess the quality of evidence and formulate recommendations. Each recommendation required ≥70% consensus among the Voting Panel. Results We present 26 recommendations and 5 ungraded position statements for GPA/MPA, and 15 recommendations and 5 ungraded position statements for EGPA. This guideline provides recommendations for remission induction and maintenance therapy as well as adjunctive treatment strategies in GPA, MPA, and EGPA. These recommendations include the use of rituximab for remission induction and maintenance in severe GPA and MPA and the use of mepolizumab in nonsevere EGPA. All recommendations are conditional due in part to the lack of multiple randomized controlled trials and/or low‐quality evidence supporting the recommendations. Conclusion This guideline presents the first recommendations endorsed by the American College of Rheumatology and the Vasculitis Foundation for the management of AAV and provides guidance to health care professionals on how to treat these diseases.
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis
Maz, Mehrdad , Abril, Andy , Langford, Carol A. , Gorelik, Mark , Archer, Amy M., Conn, Doyt L. , Full, Kathy A., Grayson, Peter C. , Ibarra, Maria, Imundo, Lisa F., Kim, Susan , Rhee, Rennie L. , Stone, John H. , Sule, Sangeeta , Vitobaldi, Omar I., Warner, Ann, Byram, Kevin , Dua, Anisha B. , Husainat, Nedaa , James, Karen , Kalot, Mohamad A. , Lin, Yih Chang, Springer, Jason , Turgunbaev, Marat, Villa‐Forte, Alexandra, Turner, Amy S. , Conn, Doyt L , Grayson, Peter C , Merkel, Peter A , Rhee, Rennie L , Stone, John H , Sule, Sangeeta , Husainat, Nedaa M , Kalot, Mohamad A , Springer, Jason M , Turner, Amy S , Mustafa, Reem A , Maz, Mehrdad , Dua, Anisha B , Chung, Sharon A. , Guyatt, Gordon , Merkel, Peter A. , Seo, Philip , Sundel, Robert P. , Warner, Ann

Mayo Clinic

Arthritis & Rheumatology | July 8, 2021 | Volume: 73 | Issue: 8 | Pages: 1349-1365

10.1002/art.41774 | PMID 34235884 Get It

Objective To provide evidence‐based recommendations and expert guidance for the management of giant cell arteritis (GCA) and Takayasu arteritis (TAK) as exemplars of large vessel vasculitis. Methods Clinical questions regarding diagnostic testing, treatment, and management were developed in the population, intervention, comparator, and outcome (PICO) format for GCA and TAK (27 for GCA, 27 for TAK). Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to rate the quality of the evidence. Recommendations were developed by the Voting Panel, comprising adult and pediatric rheumatologists and patients. Each recommendation required ≥70% consensus among the Voting Panel. Results We present 22 recommendations and 2 ungraded position statements for GCA, and 20 recommendations and 1 ungraded position statement for TAK. These recommendations and statements address clinical questions relating to the use of diagnostic testing, including imaging, treatments, and surgical interventions in GCA and TAK. Recommendations for GCA include support for the use of glucocorticoid‐sparing immunosuppressive agents and the use of imaging to identify large vessel involvement. Recommendations for TAK include the use of nonglucocorticoid immunosuppressive agents with glucocorticoids as initial therapy. There were only 2 strong recommendations; the remaining recommendations were conditional due to the low quality of evidence available for most PICO questions. Conclusion These recommendations provide guidance regarding the evaluation and management of patients with GCA and TAK, including diagnostic strategies, use of pharmacologic agents, and surgical interventions.
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Langford, Carol A. , Maz, Mehrdad , Abril, Andy , Gorelik, Mark , Archer, Amy M., Conn, Doyt L. , Full, Kathy A., Grayson, Peter C. , Ibarra, Maria, Imundo, Lisa F., Kim, Susan , Rhee, Rennie L. , Stone, John H. , Sule, Sangeeta , Vitobaldi, Omar I., Warner, Ann, Byram, Kevin , Dua, Anisha B. , Husainat, Nedaa , James, Karen , Kalot, Mohamad A. , Lin, Yih Chang, Springer, Jason , Turgunbaev, Marat, Villa‐Forte, Alexandra, Turner, Amy S. , Maz, Mehrdad , Conn, Doyt L , Grayson, Peter C , Merkel, Peter A , Rhee, Rennie L , Stone, John H , Sule, Sangeeta , Husainat, Nedaa M , Kalot, Mohamad A , Springer, Jason M , Turner, Amy S , Mustafa, Reem A , Dua, Anisha B , Chung, Sharon A. , Guyatt, Gordon , Merkel, Peter A. , Seo, Philip , Sundel, Robert P. , Warner, Ann

Mayo Clinic

Arthritis & Rheumatology | July 8, 2021 | Volume: 73 | Issue: 8 | Pages: 1366-1383

10.1002/art.41773 | PMID 34235894 Get It

Objective To provide evidence‐based recommendations and expert guidance for the management of antineutrophil cytoplasmic antibody–associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). Methods Clinical questions regarding the treatment and management of AAV were developed in the population, intervention, comparator, and outcome (PICO) format (47 for GPA/MPA, 34 for EGPA). Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to assess the quality of evidence and formulate recommendations. Each recommendation required ≥70% consensus among the Voting Panel. Results We present 26 recommendations and 5 ungraded position statements for GPA/MPA, and 15 recommendations and 5 ungraded position statements for EGPA. This guideline provides recommendations for remission induction and maintenance therapy as well as adjunctive treatment strategies in GPA, MPA, and EGPA. These recommendations include the use of rituximab for remission induction and maintenance in severe GPA and MPA and the use of mepolizumab in nonsevere EGPA. All recommendations are conditional due in part to the lack of multiple randomized controlled trials and/or low‐quality evidence supporting the recommendations. Conclusion This guideline presents the first recommendations endorsed by the American College of Rheumatology and the Vasculitis Foundation for the management of AAV and provides guidance to health care professionals on how to treat these diseases.
Fc receptor-like 5 and anti-CD20 treatment response in granulomatosis with polyangiitis and microscopic polyangiitis
Owczarczyk, Kasia , Cascino, Matthew D., Holweg, Cécile , Tew, Gaik W. , Ortmann, Ward , Behrens, Timothy W. , Langford, Carol A. , Clair, E. William St. , Merkel, Peter A. , Kallenberg, Cees G. M., Lim, Noha , Stone, John H., Brunetta, Paul , Prunotto, Marco , Merkel, Peter A , Schindler, Thomas Hellmut , Spiera, Robert , Seo, Philip , Specks, Ulrich

Mayo Clinic

JCI Insight | August 25, 2020 | Volume: 5 | Issue: 18 | Pages: No page available

10.1172/jci.insight.136180 | PMID 32841219 Get It

BACKGROUND Baseline expression of FCRL5 , a marker of naive and memory B cells, was shown to predict response to rituximab (RTX) in rheumatoid arthritis. This study investigated baseline expression of FCRL5 as a potential biomarker of clinical response to RTX in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). METHODS A previously validated quantitative PCR–based (qPCR-based) platform was used to assess FCRL5 expression in patients with GPA/MPA (RAVE trial, NCT00104299). RESULTS Baseline FCRL5 expression was significantly higher in patients achieving complete remission (CR) at 6, 12, and 18 months, independent of other clinical and serological variables, among those randomized to RTX but not cyclophosphamide-azathioprine (CYC/AZA). Patients with baseline FCRL5 expression ≥ 0.01 expression units (termed FCRL5 hi ) exhibited significantly higher CR rates at 6, 12, and 18 months as compared with FCRL5 lo subjects (84% versus 57% [ P = 0.016], 68% versus 40% [ P = 0.02], and 68% versus 29% [ P = 0.0009], respectively). CONCLUSION Our data taken together suggest that FCRL5 is a biomarker of B cell lineage associated with increased achievement and maintenance of complete remission among patients treated with RTX and warrant further investigation in a prospective manner. FUNDING The analysis for this study was funded by Genentech Inc.
The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4‐Related Disease
Wallace, Zachary S. , Naden, Ray, Chari, Suresh T. , Choi, Hyon K. , Della‐Torre, Emanuel, Dicaire, Jean‐Francois, Hart, Phil A. , Inoue, Dai , Khosroshahi, Arezou , Lanzillotta, Marco , Okazaki, Kazuichi , Perugino, Cory A. , Saeki, Takako , Sekiguchi, Hiroshi , Schleinitz, N. , Stone, James R. , Takahashi, Naoki , Umehara, Hisanori , Webster, George, Zen, Yoh , Stone, John H. , Culver, Emma , Frulloni, Luca , Lerch, Markus M. , Matsui, Shoko , Rosenbaum, James T. , Chari, Suresh, Choi, Hyon , Stone, John H , Takahashi, Naoki , Chari, Suresh T , Della‐Torre, Emanuel , Kawano, Mitsuhiro , Kubota, Kensuke , Sharma, Amita , Fernández‐Codina, Andreu

Mayo Clinic

Arthritis & Rheumatology | December 3, 2019 | Volume: 72 | Issue: 1 | Pages: 7-19

10.1002/art.41120 | PMID 31793250 Get It

Objective IgG4‐related disease (IgG4‐ RD ) can cause fibroinflammatory lesions in nearly any organ. Correlation among clinical, serologic, radiologic, and pathologic data is required for diagnosis. This work was undertaken to develop and validate an international set of classification criteria for IgG4‐ RD . Methods An international multispecialty group of 86 physicians was assembled by the American College of Rheumatology ( ACR ) and the European League Against Rheumatism ( EULAR ). Investigators used consensus exercises, existing literature, derivation and validation cohorts of 1,879 subjects (1,086 cases, 793 mimickers), and multicriterion decision analysis to identify, weight, and test potential classification criteria. Two independent validation cohorts were included. Results A 3‐step classification process was developed. First, it must be demonstrated that a potential IgG4‐ RD case has involvement of at least 1 of 11 possible organs in a manner consistent with IgG4‐ RD . Second, exclusion criteria consisting of a total of 32 clinical, serologic, radiologic, and pathologic items must be applied; the presence of any of these criteria eliminates the patient from IgG4‐ RD classification. Third, 8 weighted inclusion criteria domains, addressing clinical findings, serologic results, radiology assessments, and pathology interpretations, are applied. In the first validation cohort, a threshold of 20 points had a specificity of 99.2% (95% confidence interval [95% CI ] 97.2–99.8%) and a sensitivity of 85.5% (95% CI 81.9–88.5%). In the second, the specificity was 97.8% (95% CI 93.7–99.2%) and the sensitivity was 82.0% (95% CI 77.0–86.1%). The criteria were shown to have robust test characteristics over a wide range of thresholds. Conclusion ACR / EULAR classification criteria for IgG4‐ RD have been developed and validated in a large cohort of patients. These criteria demonstrate excellent test performance and should contribute substantially to future clinical, epidemiologic, and basic science investigations.
Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Kronbichler, Andreas , Leierer, Johannes , Shin, Jae Il , Langford, Carol A. , Hoffman, Gary S., Kallenberg, Cees G. M., Clair, E. William St. , Brunetta, Paul , Keogh, Karina A., Ytterberg, Steven R. , Stone, John H. , Shin, Jae I L , Merkel, Peter A. , Spiera, Robert , Seo, Philip , Fervenza, Fernando C. , Geetha, Duvuru , Monach, Paul A. , Mayer, Gert J. , Specks, Ulrich

Mayo Clinic

Arthritis & Rheumatology | June 19, 2019 | Volume: 71 | Issue: 11 | Pages: 1888-1893

10.1002/art.41017 | PMID 31216123 Get It

ObjectiveTo assess the frequency of venous thromboembolism (VTE) events in the Rituximab in Antineutrophil Cytoplasmic Antibody (ANCA)–Associated Vasculitis (RAVE) trial and identify novel potential risk factors.MethodsVTE events in 197 patients enrolled in the RAVE trial were analyzed. Baseline demographic and clinical characteristics were recorded, and univariate and multivariate analyses were performed to identify factors associated with VTE in ANCA‐associated vasculitis (AAV).ResultsVTE occurred in 16 patients (8.1%) with an overall average time to event of 1.5 months (range 1.0–2.75). In univariate analyses with calculation of hazard ratios (HRs) and 95% confidence intervals (95% CIs), heart involvement (HR 17.408 [95% CI 2.247–134.842]; P = 0.006), positive proteinase 3 (PR3)–ANCA (HR 7.731 [95% CI 1.021–58.545]; P = 0.048), pulmonary hemorrhage (HR 3.889 [95% CI 1.448–10.448]; P = 0.008), and the presence of red blood cell casts (HR 15.617 [95% CI 3.491–69.854]; P < 0.001) were associated with the onset of VTE. In multivariate models adjusted for age and sex, the significant associations between VTE events and heart involvement (HR 21.836 [95% CI 2.566–185.805]; P = 0.005), PR3‐ANCA (HR 9.12 [95% CI 1.158–71.839]; P = 0.036), pulmonary hemorrhage (HR 3.91 [95% CI 1.453–10.522]; P = 0.007), and urinary red blood cell casts (HR 16.455 [95% CI 3.607–75.075]; P < 0.001) remained.ConclusionPatients diagnosed as having AAV with pulmonary hemorrhage, positive PR3‐ANCA, heart involvement, and the presence of red blood cell casts are at an increased risk to develop VTE. Further studies are needed to confirm and expand these findings and to explore the mechanisms of hypercoagulability in these patients with the aim of informing potential targets for therapeutic intervention.
Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Wallace, Zachary S. , Liao, Katherine P. , Kallenberg, Cees G. M., Langford, Carol A. , Clair, E. William St. , Zhang, Yuqing , Stone, John H. , Liao, Katherine , Choi, Hyon , Fu, Xiaoqing , Merkel, Peter A. , Monach, Paul A. , Seo, Philip , Specks, Ulrich , Spiera, Robert , Choi, Hyon K.

Mayo Clinic

Arthritis & Rheumatology | June 4, 2019 | Volume: 71 | Issue: 11 | Pages: 1879-1887

10.1002/art.41006 | PMID 31162829 Get It

ObjectivePatients with antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) have an elevated risk of cardiovascular disease (CVD). This study was undertaken to develop a clearer understanding of the association between changes in disease activity and lipid levels in AAV, which may inform CVD risk stratification in this population.MethodsLipid levels were assessed in stored serum samples (obtained at baseline and month 6) from the Rituximab for ANCA‐Associated Vasculitis (RAVE) trial, which randomized patients to receive either rituximab or cyclophosphamide followed by azathioprine. Paired t‐tests and multivariable linear regression were used to assess changes in lipid levels.ResultsOf the 142 patients with serum samples available, the mean ± SD age was 52.3 ± 14.7 years, 72 (51%) were male, 95 (67%) were proteinase 3 (PR3)–ANCA positive, 72 (51%) had received a new diagnosis of AAV, and 75 (53%) were treated with rituximab. Several lipid levels increased between baseline and month 6, including total cholesterol (+12.4 mg/dl [95% confidence interval (95% CI) +7.1, +21.0]), low‐density lipoprotein (+10.3 mg/dl [95% CI +6.1, +17.1]), and apolipoprotein B (+3.5 mg/dl [95% CI +1.0, +8.3]). These changes were observed among newly diagnosed and PR3‐ANCA–positive patients but not among those with relapsing disease or myeloperoxidase‐ANCA–positive patients. There was no difference in change in lipid levels between rituximab‐treated patients and cyclophosphamide‐treated patients. Changes in lipid levels correlated with changes in erythrocyte sedimentation rate but not with other inflammatory markers or glucocorticoid exposure.ConclusionLipid levels increased during remission induction among patients with newly diagnosed AAV and those who were PR3‐ANCA positive. Disease activity and ANCA type should be considered when assessing lipid profiles to stratify CVD risk in patients with AAV.
190. DETECTION OF CIRCULATING PR3-SPECIFIC B CELLS IN PATIENTS WITH ACTIVE ANCA-ASSOCIATED VASCULITIS
Cornec, Divi, Hummel, Amber M., Peikert, Tobias, Langford, Carol A. , Clair, E. William St. , Harris, Kristina M. , Stone, John H., Abdullahad, Wayel, Specks, U., Cornec, Divi , Berti, Alvise , Carmona, Eva M. , Monach, Paul A. , Merkel, Peter A. , Seo, Philip , Spiera, Robert , Fervenza, Fernando C. , Pers, Jacques-Olivier , Heeringa, Peter , Specks, Ulrich

Mayo Clinic

Rheumatology | March 29, 2019 | Volume: 58 | Issue: Supplement_2 | Pages: No page available

10.1093/rheumatology/kez061.004 Get It

053. CLINICAL UTILITY OF SERIAL MEASUREMENTS OF ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES TARGETING PROTEINASE 3 IN ANCA-ASSOCIATED VASCULITIS
Thompson, Gwen , Fussner, Lynn A. , Hummel, Amber M., Snyder, Melissa, Kallenberg, Cees G. M., Langford, Carol A. , Clair, E. William St. , Stone, John H. , Schroeder, Darrell R. , Silva, Francisco , Snyder, Melissa, Merkel, Peter A. , Monach, Paul A. , Seo, Philip , Spiera, Robert , Specks, Ulrich

Mayo Clinic

Rheumatology | March 29, 2019 | Volume: 58 | Issue: Supplement_2 | Pages: No page available

10.1093/rheumatology/kez057.052 Get It

222. PREFERENTIAL BINDING TO AN UNEXPECTED EPITOPE OF A CHIMERIC RECOMBINANT PROTEINASE 3 VARIANT BY ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODIES
Thompson, Gwen , Nelson, Darlene R. , Fussner, Lynn A. , Hummel, Amber M., Jenne, Dieter E. , Hoffman, Gary J., Kallenberg, Cees G. M., Langford, Carol A. , McCune, Joseph W., Clair, E. William St. , Ytterberg, Steven R. , Stone, John , Moura, Marta Casal , Fervenza, Fernando C. , Hoffman, Gary, Merkel, Peter A. , Monach, Paul A. , Seo, Philip , Spiera, Robert , Stone, John, Robinson, William H. , Pang, Yuan‐Ping , Specks, Ulrich

Mayo Clinic

Rheumatology | March 29, 2019 | Volume: 58 | Issue: Supplement_2 | Pages: No page available

10.1093/rheumatology/kez061.037 Get It